Cutaneous Adverse Drug Reactions (CADR)
1 clinical trials · Condition
◉ Watch Cutaneous Adverse Drug Reactions (CADR)
| Record | Firm | Date |
|---|---|---|
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. (NCT07110662) | Hospices Civils de Lyon | 2025-10-29 |
Track Cutaneous Adverse Drug Reactions (CADR) automatically
Every clearance here is in the API, with alerts when new ones post.